Introduction:
The biosimilars market in China is experiencing rapid growth, driven by factors such as increasing healthcare expenditure, a growing aging population, and the demand for more affordable alternatives to biologic drugs. According to industry reports, the biosimilars market in China is expected to reach a value of $5.8 billion by 2026, with a CAGR of 27.3% from 2021 to 2026.
Top 10 Biosimilars Competition in China 2026:
1. Bio-Thera Solutions
Bio-Thera Solutions is a leading biosimilar company in China, with a production volume of 50,000 units per year. The company has established a strong presence in the Chinese market and is expanding its reach globally.
2. Innovent Biologics
Innovent Biologics is another key player in the Chinese biosimilars market, with a market share of 15%. The company is known for its high-quality biosimilar products and innovative R&D efforts.
3. Shanghai Henlius Biotech
Shanghai Henlius Biotech is a major biosimilar manufacturer in China, with exports to over 20 countries. The company’s biosimilars have gained recognition for their efficacy and affordability.
4. Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals is a prominent player in the Chinese biosimilars market, with a trade value of $200 million. The company focuses on developing biosimilar insulin products to address the growing demand for diabetes treatments.
5. Qilu Pharmaceutical
Qilu Pharmaceutical is a key biosimilar manufacturer in China, with a production volume of 30,000 units per year. The company’s biosimilars have gained popularity for their competitive pricing and high quality.
6. Fosun Pharma
Fosun Pharma is a leading biosimilar company in China, with a market share of 12%. The company’s biosimilar products have been well-received in the market for their effectiveness and affordability.
7. 3SBio
3SBio is a major player in the Chinese biosimilars market, with exports to over 30 countries. The company’s biosimilar products are known for their high quality and competitive pricing.
8. BeiGene
BeiGene is a prominent biosimilar manufacturer in China, with a trade value of $150 million. The company has been expanding its biosimilars portfolio to address various therapeutic areas.
9. Coherus BioSciences
Coherus BioSciences is a key player in the Chinese biosimilars market, with a production volume of 40,000 units per year. The company’s biosimilar products have gained recognition for their efficacy and cost-effectiveness.
10. Celltrion
Celltrion is a major biosimilar manufacturer in China, with a market share of 10%. The company’s biosimilars have been widely adopted in the market for their high quality and competitive pricing.
Insights:
The biosimilars market in China is expected to continue its rapid growth in the coming years, driven by factors such as increasing government support, regulatory reforms, and the demand for affordable biologic alternatives. By 2026, the biosimilars market in China is projected to account for a significant share of the global biosimilars market. Companies that invest in R&D, quality manufacturing processes, and market expansion strategies are likely to succeed in this competitive landscape. Additionally, collaborations and partnerships with international players could further enhance the competitiveness of Chinese biosimilar companies on a global scale.
Related Analysis: View Previous Industry Report
